Every 10-Q that Vivos Therapeutics, Inc. (VVOS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VVOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VVOS filings page.
Vivos Therapeutics, Inc. reports sharply higher revenue but deeper losses and mounting liquidity pressure for the three and six months ended June 30, 2026. Total revenue rose to $5.2M for the quarter and $10.3M year-to-date, up from $3.8M and $6.8M, driven mainly by growth in sleep testing services and new treatment center revenue tied to its pivot toward medical-provider alliances and the prior acquisition of The Sleep Center of Nevada.
Despite higher gross profit, operating expenses increased to $7.8M for the quarter and $17.5M year-to-date, producing an operating loss of $11.4M for the first half and a net loss attributable to stockholders of $13.2M. Cash used in operations was $9.2M in six months, leaving only $1.8M of cash against $28.1M of total liabilities and a stockholders’ deficit of $(3.8)M. Management explicitly states that these conditions and expected cash needs raise substantial doubt about the company’s ability to continue as a going concern and indicates reliance on continued equity and debt financing, including recent PIPE offerings, warrant exercises, ATM sales, and high-cost debt with original issue discounts, to fund operations and support Nasdaq listing compliance.
Vivos Therapeutics reports first-quarter 2026 revenue of $5.1M, up from $3.0M a year earlier, driven mainly by higher sleep testing and treatment center service revenue. Despite this growth, the company posted a net loss of $7.8M, widening from $3.9M. Operating cash outflow was $6.0M, leaving cash and equivalents at $2.1M against total liabilities of $26.3M and an accumulated deficit of about $133M. Management states that existing cash will not fund operations for the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern without additional financing. The quarter also reflects integration of the 2025 Sleep Center of Nevada acquisition, which added service revenue but has not yet offset the higher costs and debt taken on for the deal.
Vivos Therapeutics, Inc. reported sharply higher revenue but widening losses for the quarter ended September 30, 2025, while highlighting substantial doubt about its ability to continue as a going concern. Quarterly revenue rose to $6.8 million from $3.9 million a year earlier, driven mainly by growth in service revenue such as sleep testing, treatment centers and billing services. For the nine months, revenue increased to $13.6 million from $11.3 million.
Despite this growth, the company posted a net loss of $5.4 million for the quarter and $14.3 million for the nine months, with higher general and administrative costs and depreciation tied to its expanding operations. Cash and cash equivalents were $3.1 million at September 30, 2025, versus total liabilities of $23.1 million, and stockholders’ equity fell to $2.5 million from $8.0 million at year-end 2024.
Vivos completed an $8.7 million acquisition of The Sleep Center of Nevada, funded partly by an $8.3 million senior secured note and new equity, adding goodwill and intangible assets and expanding its new sleep-center based distribution model. Management notes ongoing operating cash burn of $11.5 million year-to-date and states that existing cash will not fund operations for the next 12 months without additional financing.
Vivos Therapeutics, Inc. (VVOS) reported interim financial results reflecting recent acquisition activity and constrained liquidity. The company completed an acquisition (SCN) with total preliminary consideration of about $8.7 million, including $6.0 million cash, 607,287 restricted shares valued at $1.3 million and contingent earn‑out equity estimated at $1.4 million. Goodwill rose to $5.6 million and identifiable intangible assets of $1.9 million were recorded.
For the six months ended June 30, 2025, the company had revenues reported in the periods shown (examples: $3.8 million and $4.1 million in comparative periods shown), operating losses (e.g., $(4.9) million and $(1.9) million in shown periods) and an accumulated deficit of approximately $113.1 million. Cash and cash equivalents were about $4.4 million with total liabilities of approximately $21.5 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern absent additional financing. The company completed financing transactions in 2024–2025 including private placements and PIPE proceeds totaling several million dollars (including $2.7 million received in June 2025 and $3.7 million upon conversion of a bridge note).